 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Who Gets Antiviral Treatment for Hepatitis C?
19 February 2002 | Volume 136 Issue 4 | Page I48
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C." It is in the 19 February 2002 issue of Annals of Internal Medicine (volume 136, pages 288-292). The authors are Y Falck-Ytter, H Kale, KD Mullen, SA Sarbah, L Sorescu, and AJ McCullough.
What is the problem and what is known about it so far?
Hepatitis is an inflammation of the liver that can be caused by several things, including alcohol, drugs, and viruses. Many people with hepatitis recover within a few months, but hepatitis can be chronic and progress to scarring of the liver (cirrhosis). Hepatitis C virus can cause chronic hepatitis infection, cirrhosis, or liver failure and can increase the risk for liver cancer. People become infected with the hepatitis C virus through sexual intercourse or by sharing contaminated needles with persons who are already infected. Strong antiviral drugs can kill hepatitis C virus, but these drugs are difficult to take and have many side effects. Patients taking these drugs must be followed closely and have liver biopsies analyzed. Doctors usually won't give antiviral drugs to people who drink too much, "shoot up" drugs, have severe liver disease or other serious medical problems, are pregnant or unwilling to practice contraception, or suffer from severe psychiatric problems. The studies showing that antiviral therapies work have been done in people without any of these problems. We do not know whether most patients with hepatitis C virus infection have such problems and cannot take antiviral therapy.
Why did the researchers do this particular study?
To find out how many patients with hepatitis C virus infection are good candidates for antiviral therapy.
Who was studied?
327 patients who were referred to a special liver clinic for possible antiviral treatment for hepatitis C virus infection. The clinic was in a large county hospital in Cleveland, Ohio.
How was the study done?
The researchers reviewed the medical records of patients who had been referred to the clinic in 1998 and 1999. They used notes of clinic doctors to determine how many patients were not treated and why.
What did the researchers find?
Of the 327 patients, 34 did not have chronic hepatitis C virus infection. Of the remaining patients, 72% were not treated with antiviral therapy. Patients were not treated for several reasons, including failure to show up for appointments or to have necessary tests (37%), severe medical or psychiatric problems (34%), ongoing alcohol or drug abuse (13%), or not wanting treatment (11%).
What were the limitations of the study?
The study setting was one large county clinic in an urban area. We do not know whether patients attending clinics in other areas would have the same or different characteristics.
What are the implications of the study?
Many patients with hepatitis C virus are not good candidates for antiviral therapies.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. Dieperink, J. Leskela, M. E. Dieperink, B. Evans, P. Thuras, and S. B. Ho The Effect of Pegylated Interferon-{alpha}2b and Ribavirin on Posttraumatic Stress Disorder Symptoms Psychosomatics, May 1, 2008; 49(3): 225 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rousseau, G. N. Ioannou, J. A. Todd-Stenberg, K. L. Sloan, M. F. Larson, C. W. Forsberg, and J. A. Dominitz Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort Study Am J Public Health, May 1, 2008; 98(5): 846 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Schackman, P. A. Teixeira, G. Weitzman, A. I. Mushlin, and I. M. Jacobson Quality-of-Life Tradeoffs for Hepatitis C Treatment: Do Patients and Providers Agree? Med Decis Making, April 1, 2008; 28(2): 233 - 242. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Rifai, J. K. Moles, and D. D. Short Hepatitis C Treatment Eligibility and Outcomes Among Patients With Psychiatric Illness Psychiatr Serv, April 1, 2006; 57(4): 570 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rifai, J. K. Moles, L. P. Lehman, and B. J. Van der Linden Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics, March 1, 2006; 47(2): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Hughes and S. D Shafran Treatment of Hepatitis C in HIV-Coinfected Patients Ann. Pharmacother., March 1, 2006; 40(3): 479 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Santaguida, M. Helfand, and P. Raina Challenges in Systematic Reviews That Evaluate Drug Efficacy or Effectiveness Ann Intern Med, June 21, 2005; 142(12_Part_2): 1066 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Barth, A. Ulsenheimer, G. R. Pape, H. M. Diepolder, M. Hoffmann, C. Neumann-Haefelin, R. Thimme, P. Henneke, R. Klein, G. Paranhos-Baccala, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells Blood, May 1, 2005; 105(9): 3605 - 3614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Hernandez-Santiago, T. Beltran, L. Stuyver, C. K. Chu, and R. F. Schinazi Metabolism of the Anti-Hepatitis C Virus Nucleoside {beta}-D-N4-Hydroxycytidine in Different Liver Cells Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4636 - 4642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Matthews and E. J. Bini Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C Journal of Pharmacy Practice, August 1, 2004; 17(4): 229 - 238. [Abstract] [PDF]
|
|
|
|
|
|
H. B. El-Serag Prevention of Hepatocellular Carcinoma Ann Intern Med, July 6, 2004; 141(1): 77 - 78. [Full Text] [PDF]
|
|
|
|
|
|
R. Chou, E. C. Clark, and M. Helfand Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, March 16, 2004; 140(6): 465 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Rocca, B. P. Yawn, P. Wollan, and W. R. Kim Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat Ann. Fam. Med, March 1, 2004; 2(2): 116 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Koretz Update in Gastroenterology Ann Intern Med, September 2, 2003; 139(5_Part_1): 352 - 358. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Allen, A. C. Spaulding, A. M. Osei, L. E. Taylor, A. M. Cabral, and J. D. Rich Treatment of Chronic Hepatitis C in a State Correctional Facility Ann Intern Med, February 4, 2003; 138(3): 187 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Hammett Adopting More Systematic Approaches to Hepatitis C Treatment in Correctional Facilities Ann Intern Med, February 4, 2003; 138(3): 235 - 236. [Full Text] [PDF]
|
|
|
|
|
|
C. Diamond and J. H. Lee Use of Antiviral Therapy in Patients with Hepatitis C Ann Intern Med, December 17, 2002; 137(12): 1012 - 1012. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Herrine Approach to the Patient with Chronic Hepatitis C Virus Infection Ann Intern Med, May 21, 2002; 136(10): 747 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Hepatitis C: Few Candidates for Modestly Effective Treatment Journal Watch Pediatrics and Adolescent Medicine, May 13, 2002; 2002(513): 12 - 12. [Full Text]
|
|
|
|
 |
|
 Hepatitis C: Few Candidates for Modestly Effective Treatment Journal Watch (General), March 5, 2002; 2002(305): 1 - 1. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
